First approved for adults in 2022, the therapy is now cleared for children 12-18 with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|July 26, 2004
Antitussive offers convenient twice-daily dosing
The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.
Advertisement
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.
With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.
Advertisement
Advertisement
Trending on Drug Topics
1
What Is HIV PrEP and Who Needs It Most?
2
Normal vs. Concerning COVID-19 Vaccine Reactions: A Pharmacist's Guide
3
Validating Fear Before Facts: A Framework for COVID-19 Hesitancy
4
Why Rural Pharmacies Are Essential Infrastructure in US Health Care
5